Zobrazeno 31 - 40
of 233
pro vyhledávání: '"Richard F. Little"'
Autor:
Ajay K. Nooka, Joseph M. Unger, Rachel Kobos, Khalid Mezzi, Mihaela Popa-McKiver, Lola Fashoyin-Aje, Yelak Biru, Richard F. Little, Nicole J. Gormley, Kenneth C. Anderson, Tiffany H. Williams, Trevan Locke
Publikováno v:
Blood Cancer Discov
African Americans are at higher risk of multiple myeloma (MM) yet are underrepresented in clinical trials and reap fewer benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers,
Autor:
Kathryn Lurain, Ramya Ramaswami, Stefania Pittaluga, Elaine S. Jaffe, Jomy M. George, Seth M. Steinberg, Mark N. Polizzotto, Priscila H. Goncalves, Richard F. Little, Vickie Marshall, Adam Rupert, Hao-Wei Wang, Ralph Mangusan, Robert Yarchoan, Kirsta Waldon, Denise Whitby, Thomas S. Uldrick, Irene Ekwede, Anaida Widell
Publikováno v:
Blood Adv
Kaposi sarcoma (KS)-associated herpesvirus (KSHV)–associated multicentric Castleman disease (MCD) is a relapsing and remitting systemic lymphoproliferative disorder characterized by severe inflammatory symptoms most common among people living with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146ec5c676903f36389d85eb63f83d20
https://europepmc.org/articles/PMC7993110/
https://europepmc.org/articles/PMC7993110/
Autor:
Elaine S. Jaffe, John Hayslip, Paolo Caimi, Richard F. Little, Stefania Pittaluga, Jeremy S. Abramson, Ariela Noy, Jonathan W. Friedberg, Nancy L. Bartlett, Sunil Nagpal, Kieron Dunleavy, Michelle A. Fanale, Samir Parekh, Brad S. Kahl, Rakesh Gaur, Seth M. Steinberg, Mark Roschewski, Deepa Jagadeesh, Ann S. LaCasce, Andrea Nicole Lucas, Mary Jo Lechowicz, Christopher Melani, Wyndham H. Wilson
Publikováno v:
The Lancet Haematology. 5:e609-e617
Summary Background MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vin
Autor:
Kathryn Lurain, Richard F. Little, Howard Streicher, Ravie Kem, Jared C. Foster, Elad Sharon, Joshua E. Reuss, Diana Stern, Ramya Ramaswami, Helen X. Chen
Publikováno v:
JAMA Network Open
Key Points Question Has inclusion of people living with HIV in anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immunotherapy trials changed during ongoing Cancer Therapy Evaluation Program advocacy efforts by the Nati
Autor:
S. Percy Ivy, Richard F. Little
Publikováno v:
Cancer Pharmacology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bf6caf9d2772f31b17a458afe9474d7
https://doi.org/10.1891/9780826162045.0017
https://doi.org/10.1891/9780826162045.0017
Autor:
Ralph Mangusan, Robert Yarchoan, Hao-Wei Wang, Ramya Ramaswami, Vickie Marshall, Denise Whitby, Richard F. Little, Thomas S. Uldrick, Anaida Widell, Kathryn Lurain, Elaine S. Jaffe, Stefania Pittaluga, Krithika Shanmugasundaram, Mark N. Polizzotto
Publikováno v:
Blood. 138:1437-1437
Background: Primary effusion lymphoma (PEL) is a rare, B cell non-Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8, that is strongly associated with HIV infection. PEL often presents as malignant b
Autor:
Priyanka A. Pophali, Amanda F. Cashen, Anthony R. Mato, Mark R. Litzow, Steven Coutre, Lynne I. Wagner, Cong Christine Zhang, Neil E. Kay, Fengmin Zhao, Mary L. Thomas, Jose F. Leis, Richard Stone, Paul M. Barr, Martin S. Tallman, Tait D. Shanafelt, Jacqueline C. Barrientos, Richard F. Little, Susan O'Brien, Elisabeth Paietta, Avina K. Singh, Harry P. Erba, Xin Victoria Wang, Curtis A. Hanson
Publikováno v:
Blood. 138:1562-1562
Background: The ECOG-ACRIN randomized phase 3 clinical trial E1912 established ibrutinib-rituximab (IR) as the standard of care for CLL patients Methods: Patients enrolled on E1912 completed the Functional Assessment of Cancer Therapy-General (FACT-G
Autor:
Andrew G. Hatch, James H. Doroshow, Erin M. Mosher, Christopher S. Hourigan, Srikrishna K. Narava, Maria Saeed, Laura W. Dillon, Shahanawaz Jiwani, Seth Sadis, Richard F. Little, Denis Kaznadzey, P. Mickey Williams, Marvin S. Majano, Georgia M. Andrew, Vinay K. Mittal, Ting-Chia Chang, Anna Lee-Fong, Lyndsay Harris, John N. Zhang, Marina Sedova, Jiajie Huang, Jeffery M. Smith, Jingwei Ni
Publikováno v:
Blood. 138:4444-4444
Background: In the last decade there have been significant advances in diagnosing and classifying adult acute myeloid leukemia (AML) based on genomic profiling, enabling risk-stratification and targeted therapies. In 2017 the US FDA approved the firs
Autor:
Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Publikováno v:
Blood. 138:3728-3728
Background The phase 3 trial A041202 solidified the Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib as a standard of care for older patients with previously untreated CLL by showing superior progression-free survival (PFS) as compared with bendamu
Autor:
Jeremy S. Abramson, Eric D. Hsi, Daniel J. Landsburg, Steven D. Gore, Richard F. Little, John P. Leonard, Sharmila Giri, Nancy L. Bartlett, Anusha Vallurupalli, Jonathan W. Friedberg, Brad S. Kahl, Amy S. Ruppert, Ann Hudson
Publikováno v:
Blood. 138:523-523
Background: High grade B-cell Lymphoma with rearrangements of MYC and BCL2 and/or BCL6, also known as double hit lymphoma (DHL), and double expressing lymphomas (DEL; DLBCL with IHC expression of MYC and BCL2, but without double hit cytogenetics) are